INTRODUCTION
Anemia is a leading cause of morbidity and mortality worldwide, affecting up to two-thirds of children in most developing countries. 1, 2 According to WHO, iron deficiency is the commonest nutritional deficiency in developing countries. Young children are most vulnerable for developing iron deficiency anemia (IDA), owing to their high iron requirements during growth. 3 Anemia also impairs cognitive performance, behavioral and motor development, coordination, language development and scholastic achievement. 4 In India, nearly 75% of children 45 years of age suffer from anemia. The National Family Health Survey-III data indicates that the prevalence of anemia in preschool children continues to be high throughout India. 5 Although anemia is multifactorial in etiology, it is generally assumed that at least half the burden is attributable to iron deficiency. 1 In India, the National Nutritional Anemia Control Program (NNACP) for prevention of anemia recommends iron (20 mg) and folic acid (100 mg) (IFA) tablet supplementation for 100 days every year for children between 1 and 5 years of age. 6 Despite decades of existence of this program, the prevalence of childhood anemia has not declined. The implementation of IFA supplementation under NNACP is severely deficient, and a supervised weekly supplementation regime has been advocated to improve compliance. Conversely, it has been suggested that the prophylactic iron supplementation dosage should be enhanced to near therapeutic levels to account for the high prevalence of anemia (B75%). There is paucity of relevant evidence in the Indian context to inform policy. We therefore conducted a cluster randomized controlled trial to compare the efficacy of two dosages of daily (20 mg iron and 100 mg folic acid, or 40 mg iron and 200 mg folic acid) and weekly (40 mg iron and 200 mg folic acid) IFA supplementation in improving hemoglobin content in 3-5 years old children with mild or moderate anemia.
MATERIALS AND METHODS
India. The trial was conducted by utilizing the existing government infrastructure. The population attached to nine Anganwadi centers (AWCs) in this Block (clusters) were randomized into three equal groups of three clusters each using block randomization procedure with variable block size. Randomization sequence was generated by a statistician who was not in the part of the study. Research Assistant enrolled the eligible children from the identified clusters (AWCs).
It was an open label study, that is, no blinding was done. Children between the ages of 3 and 5 years residing in the AWC areas were then enlisted and screened for enrollment including hemoglobin estimation. The inclusion criteria for enrollment were: (i) age between 3 and 5 years, (ii) mild-to-moderate anemia (estimated hemoglobin between 7 and 10.9 g/dl), (iii) permanent resident of the AWC area, (iv) no plan to outmigrate during the trial duration and (v) parental consent. The exclusion criteria were: (i) severe anemia (hemoglobin o7 g/dl), (ii) severe illness requiring hospitalization, (iii) severe acute malnutrition (weight for height o À 3 s.d.) or visible severe wasting and (iv) documented chronic illnesses (hospital or practitioner records), these included tuberculosis, congenital heart disease, mailignancies, respiratory infection, renal or liver disease.
Among the 450 subjects satisfying the inclusion criteria, 426 were enrolled in the three groups (Figure 1 ). The sequential loss to follow-up was comparable in the three arms; 385 (90.3%) and 336 (78.9%) participants were available for follow-up after 50 and 100 days intervention, respectively. Out-migration from the trial area was the major reason for the loss to follow-up (15%, or 64 of the 90 participants lost to follow-up).
A questionnaire was administered to the mother or care giver for eliciting the information on demographic profile including age, gender and educational qualification, occupation and family income of the head of the family. The socio-economic status of the child's family was assessed using modified Kuppuswamy Classification, 2007. 7 History of any chronic diseases and current morbidity status of participants was also elicited. At enrollment, all participants were administered anti-helmintic treatment (albendazole syrup, single dose of 400 mg).
IFA tablets (20 mg iron and 100 mg folic acid) were procured from Cyano Pharma (P) Ltd., Indore, India; their pharmacological content was verified independently before use. IFA tablets were administered daily or weekly in a directly supervised manner by field workers. In 10% of children, domiciliary visits were conducted by the first author (UK) to validate this process. Group A (NNACP daily dose) participants received a single IFA tablet (20 mg iron and 100 mg folic acid) daily for 100 days; group B (daily dose doubled) subjects received two IFA tablets (40 mg iron and 200 mg folic acid) daily for 100 days; and group C (weekly dose) children received two IFA tablets (40 mg iron and 200 mg folic acid) once a week on a fixed day for 15 weeks.
The principle of adhering to the prevalent NNACP guidelines necessitated dispensation of IFA as tablets. Consequently, the age range was restricted to 3-5 years as younger children may experience difficulties in swallowing tablets. The high dosage participants (group B) were given twice the recommended NNACP dose, as it provided the lower range of therapeutic dose (B3 mg/kg of elemental iron) 8 on the basis of expected average weight. For the weekly dose (group C), we used two tablets to strike a balance between tolerance due to potential side effects and the reduction in supplementation amount per week (estimated dose B0.5 mg/ kg/day); one tablet/week would have severely compromised the supplementation content.
Capillary blood samples were collected at the baseline and after 50 and 100 days of IFA intervention. Hemoglobin was estimated by the Cynmeth hemoglobin method in batches of 20 samples. Commercially available samples (low and high hemoglobin range) were used for quality control; the estimates were within acceptable range. The laboratory technician was blinded to the IFA supplementation group.
The project was approved by the ethical committee of All India Institute of Medical Sciences. Written informed consent was obtained from parents Reason(s) for loss to follow up:
• Left the study area (n=24)
Reason(s) for loss to follow up:
• Left the study area (n=13)
• Discontinued intervention (n=13):
• Left the study area (n=27)
• Other reasons like occurrence of disease (n=02) Figure 1 . Trial flow Individual level baseline characteristics of children in the three groups were compared to detect any imbalance by one-way analysis of variance (quantitative variables) and w 2 test or Fischer exact tests (categorical variables). The cluster level (AWCs) characteristics were similar across the three arms. One-way analysis of variance using the Generalized Estimating Equation, with AWC's as clusters, was used to compare the confounder adjusted difference in hemoglobin change in the three groups. A twotailed P-value o0.05 denoted statistical significance.
RESULTS
There were no significant differences in the baseline characteristics of subjects who were available and lost to follow-up at least 50 days after intervention (data not presented). Table 1 compares the individual level baseline characteristics among the three groups. Participants in the weekly supplementation group were significantly younger and non-vegetarian and had higher baseline hemoglobin. A significantly greater proportion of participants belonged to the nuclear family setup in the NNACP daily dose group. We therefore adjusted for baseline hemoglobin, age, food habit and type of family in the confounder controlled analysis for hemoglobin. The mean (s.d.) iron dosage (mg/kg/day) received by children was 1.5 (0.2), 2.9 (0.5) and 0.4 (0.1) in groups A, B and C, respectively. No child in either of the groups withdrew from the trial owing to intolerance to the drug or reported side effects. Table 2 depicts the mean ± s.d. of adjusted hemoglobin levels in the three groups after 50 and 100 days of supervised supplementation. Overall, there was a significant difference among the three groups (Po0.001). At 50 days, there were no differences between the three groups, but at 100 days, adjusted hemoglobin was lowered in the weekly supplementation group. At 100 days, the mean (95% CI) differences of hemoglobin concentration (g/dl) among the three groups were: (i) A-B: À 0.05 ( À 0.17, 0.05), (ii) A-C: À 0.38 ( À 0.50, À 0.27) and (iii) B-C: À 0.33, ( À 0.45, À 0.21).
After 100 days of intervention, the number (%) of non-anemic subjects in groups A (NNACP daily dose), B (daily dose doubled) and C (weekly dose) were 21 (18.8), 21 (18.4) and 12 (10.9), respectively (P ¼ 0.198). The corresponding proportions (%) for subjects with moderate anemia (hemoglobin 7-9.9 g/dl) at baseline were 16/97 (16.5), 14/99 (14.1) and 4/84 (4.8), respectively, (P ¼ 0.04). Findings of the study are generalizable to all the children with inclusion and exclusion criteria as mentioned in the method section.
DISCUSSION
In 3-5-year-old children with mild-to-moderate anemia, 100 days of directly supervised iron-folate supplementation at NNACP (20 mg iron and 100 mg folic acid) or double (40 mg iron and 200 mg folic acid) dose is equally efficacious in elevating hemoglobin and reducing anemia. Weekly regimen (15 doses of 40 mg iron and 200 mg folic acid) is inferior to daily dosage (0.3-0.4 g/dl lower hemoglobin response). Even with daily regimens, anemia reduction was only 18-19%.
Strengths and limitations
This cluster randomized efficacy trial on subjects belonging to lower and lower-middle socio-economic strata, utilized the existing programmatic infrastructure in peri-urban area. The pharmacological content of the iron-folate tablets was Weight for height À 0.9 ± 0.9 À 0.9 ± 0.9 À 0.9 ± 0.9 0.97 Baseline hemoglobin (g/dl)
8.8 ± 1.0 8.9 ± 0.9 9.3 ± 0.8 0.001 Table 2 . Comparison of adjusted a mean±s.d. hemoglobin levels (g/dl) in the three groups after 50 and 100 days of supplementation Relative efficacy of iron-folate supplementation U Kapil et al independently verified prior to use. Compliance was ensured through directly supervised intake of tablets throughout the entire NNACP recommended duration of intervention (100 days); the effect sizes, therefore, represent the best estimates. At enrollment, all participants were administered albendazole to overcome the potential contribution of helminthiasis. Although the intervention dosage arm could not be masked, hemoglobin was estimated in a blinded manner with strict quality control measures.
The following limitations merit consideration. First, only 3-5 year-old children were recruited because younger subjects experience problems in consuming tablets, which was the recommended formulation of NNACP program at that time. However, the prevalence of anemia is highest below 2 years of age when the contribution of iron-folate deficiency to anemia may be different. Second, only participants with mild-to-moderate anemia were recruited, which may underestimate the potential role of iron-folate supplementation in addressing the anemia burden at the population level because the prophylactic aspect is not evaluated. Third, investigations were not performed to evaluate other causes of anemia and laboratory markers of iron deficiency and infection. However, this limitation would have been largely overcome with effective randomization. Fourth, the sequential loss to follow-up, predominantly due to migration, was 10% and 21% after 50 and 100 days of intervention, respectively. However, this quantum of loss to follow-up is not unusual in such community trial settings, and there were no differences in baseline characteristics among those available and lost to follow-up; we therefore do not expect a differential bias in hemoglobin response. Finally, the ideal follow-up duration should have been 1 year (start of next supplementation cycle) to evaluate the residual effect of intervention.
Comparison with earlier data Weekly supplementation resulted in slight improvement of hemoglobin and anemia, but was inferior to daily supplementation regimens. This finding is in consonance with the results of a recent Cochrane review on intermittent iron supplementation in children below 12 years of age. 9 In comparison to daily regimens, intermittent supplementation resulted in a lower hemoglobin response (mean difference (MD) À 0.60 g/l, 95% CI À 1.54-0.35, 19 studies), ferritin concentrations (MD À 4.19 mg/l, 95% CI À 9.42-1.05, 10 studies) and an increased risk of anemia (relative risk (RR) 1.23, 95% CI 1.04-1.47, 6 studies). Data on adherence were scarce and it tended to be higher among those children receiving intermittent supplementation. Directly supervised administration of supplements, as in our trial, may have inflated these computed differences.
The standard pediatric textbook recommendation for treating IDA is 3-6 mg/kg of elemental iron/day, with the higher dose being reserved for more severe cases. 8 We were surprised to observe an equivalent hemoglobin response with lower iron dosage (B1.5 mg/kg/day). However, two trials from India 10 and Ghana 11 in mild and moderately anemic (hemoglobin 7-10 g/dl), 6-18-months-old children and also documented comparable hemoglobin response with 12.5, 20 or 30 mg elemental iron per day provided as microencapsulated powder ('sprinkles'), which also contained additional micronutrients. An equivalent response was documented with 20 and 12.5 mg elemental iron drops in the Indian and Ghanian trials, respectively. A recent randomized controlled trial in 1268 pregnant women (43% anemic) in rural Burkina Faso also documented comparable hemoglobin response with 30 mg iron, folic acid and 13 other micronutrients, or with 60 mg iron and folic acid. 12 A systematic review evaluating the effect of iron intake on iron status concluded that that iron supplementation significantly improved iron status but with high levels of heterogeneity; however, supplementation dose was not a significant predictor of hemoglobin response. 13 It would be prudent to further validate the emerging evidence that lower than traditionally recommended iron doses may be effective but with lower adverse effects. There is a paucity of trials evaluating the effect of varying doses of folic acid on hematological response. We documented a relatively lower response of anemia (18-19%) to iron-folate supplementation. A systematic review suggested that, on average, in non-malarial regions 38-62% of baseline anemia in preschool children is responsive to iron supplementation; the corresponding range for malarial hyperendemic regions is 6-32%. 14 In the microencapsulated multimicronutrient powder trial in rural Pune, between 53 and 64% of 6-18-months-old participants did not have anemia at the end of 8 weeks of unsupervised supplementation. 10 Suboptimal compliance does not explain the lower response because iron-folate was administered under direct supervision. Similarly, baseline deworming excludes helminthiasis as a potential explanation. It is therefore likely that the contribution of ironfolate with deworming to anemia responsiveness in 3-5-year-old children in peri-urban Delhi is proportionately lower and additional causes, including infections, other micronutrients and hemoglobinopathies are important contributors.
Implications for policy Even supervised iron-folate supplementation alone addresses only a small proportion of childhood anemia in these settings. In the National Nutrition Monitoring Bureau evaluation in rural areas of eight states, only 3.8% of 1-5-year-old children received ironfolate supplements. 15 The expectations under realistic programmatic conditions would therefore be further compromised or negligible. There is an urgent programmatic need to introduce additional interventions that address other causes of anemia.
The NNACP recommended dose of iron-folate supplementation should be persisted with because an increased dosage is unlikely to yield any hematological benefit but may be associated with greater adverse effects. Notwithstanding the inferior hematological response with weekly administration, it would be worthwhile experimenting with this feasible regimen under direct supervision to counteract poor program implementation issues. This approach is also reported to have economic advantages and lower adverse effects.
Implications for further research
The following issues deserve priority consideration for future work on childhood anemia: (i) etiological causes under varied contexts, (ii) role of additional interventions addressing other causes of anemia, preferably in an integrated manner, (iii) validation of equivalent hematological efficacy and less adverse effects with lower iron-folate doses and (iv) evaluation of higher iron dosage (43 mg/kg/day).
